17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Substantial evidence indicates that cytophilic IgG responses to Plasmodium  falciparum merozoite antigens play a role in protection from malaria. The specific targets mediating immunity remain unclear. Evaluating antibody responses in infants naturally-exposed to malaria will allow to better understand the establishment of anti-malarial immunity and to contribute to a vaccine development by identifying the most appropriate merozoite candidate antigens.

          Methods

          The study was based on parasitological and clinical active follow-up of infants from birth to 18 months of age conducted in the Tori Bossito area of southern Benin. For 399 infants, plasma levels of cytophilic IgG antibodies with specificity for five asexual stage malaria vaccine candidate antigens were determined by ELISA in infants’ peripheral blood at 6, 9, 12 and 15 months of age. Multivariate mixed logistic model was used to investigate the association between antibody levels and anti-malarial protection in the trimester following the IgG quantification. Moreover, the concentrations of merozoite antigen-specific IgG were compared between a group of infants apparently able to control asymptomatic malaria infection (CAIG) and a group of infants with no control of malaria infection (Control group (NCIG)). Protective effect of antibodies was also assessed after 15 months of malaria exposure with a Cox regression model adjusted on environmental risk.

          Results

          Cytophilic IgG responses to AMA1, MSP1, MSP2-3D7, MSP2-FC27, MSP3 and GLURP R2 were associated with increasing malarial infection risk in univariate analysis. The multivariate mixed model showed that IgG1 and IgG3 to AMA1 were associated with an increased risk of malarial infection. However infants from CAIG (n = 53) had significantly higher AMA1-, MSP2-FC27-, MSP3-specific IgG1 and AMA1-, MSP1-, MSP2-FC27-, MSP3 and GLURP-R2-specific IgG3 than those from NCIG (n = 183). The latter IgG responses were not associated with protection against clinical malaria in the whole cohort when protective effect is assessed after 15 months of malaria exposition.

          Conclusion

          In this cohort, merozoite antigen-specific cytophilic IgG levels represent a marker of malaria exposure in infants from 6 to 18 months of age. However, infants with resolution of asymptomatic infection (CAIG) seem to have acquired naturally immunity against P. falciparum. This observation is encouraging in the context of the development of multitarget P. falciparum vaccines.

          Related collections

          Most cited references48

          • Record: found
          • Abstract: found
          • Article: not found

          Human Antibodies Fix Complement to Inhibit Plasmodium falciparum Invasion of Erythrocytes and Are Associated with Protection against Malaria

          Summary Antibodies play major roles in immunity to malaria; however, a limited understanding of mechanisms mediating protection is a major barrier to vaccine development. We have demonstrated that acquired human anti-malarial antibodies promote complement deposition on the merozoite to mediate inhibition of erythrocyte invasion through C1q fixation and activation of the classical complement pathway. Antibody-mediated complement-dependent (Ab-C′) inhibition was the predominant invasion-inhibitory activity of human antibodies; most antibodies were non-inhibitory without complement. Inhibitory activity was mediated predominately via C1q fixation, and merozoite surface proteins 1 and 2 were identified as major targets. Complement fixation by antibodies was very strongly associated with protection from both clinical malaria and high-density parasitemia in a prospective longitudinal study of children. Ab-C′ inhibitory activity could be induced by human immunization with a candidate merozoite surface-protein vaccine. Our findings demonstrate that human anti-malarial antibodies have evolved to function by fixing complement for potent invasion-inhibitory activity and protective immunity.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development.

            The development of effective malaria vaccines and immune biomarkers of malaria is a high priority for malaria control and elimination. Ags expressed by merozoites of Plasmodium falciparum are likely to be important targets of human immunity and are promising vaccine candidates, but very few Ags have been studied. We developed an approach to assess Ab responses to a comprehensive repertoire of merozoite proteins and investigate whether they are targets of protective Abs. We expressed 91 recombinant proteins, located on the merozoite surface or within invasion organelles, and screened them for quality and reactivity to human Abs. Subsequently, Abs to 46 proteins were studied in a longitudinal cohort of 206 Papua New Guinean children to define Ab acquisition and associations with protective immunity. Ab responses were higher among older children and those with active parasitemia. High-level Ab responses to rhoptry and microneme proteins that function in erythrocyte invasion were identified as being most strongly associated with protective immunity compared with other Ags. Additionally, Abs to new or understudied Ags were more strongly associated with protection than were Abs to current vaccine candidates that have progressed to phase 1 or 2 vaccine trials. Combinations of Ab responses were identified that were more strongly associated with protective immunity than responses to their single-Ag components. This study identifies Ags that are likely to be key targets of protective human immunity and facilitates the prioritization of Ags for further evaluation as vaccine candidates and/or for use as biomarkers of immunity in malaria surveillance and control.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa.

              There is longstanding evidence that immunoglobulin G (IgG) has a role in protection against clinical malaria, and human antibodies of the cytophilic subclasses are thought to be particularly critical in this respect. In this cohort study, 286 Burkinabè children 6 months to 15 years old were kept under malaria surveillance in order to assess the protective role of antibody responses against four antigens which are currently being evaluated as vaccine candidates: apical membrane antigen 1 (AMA1), merozoite surface protein 1-19 (MSP1-19), MSP3, and glutamate-rich protein (GLURP). Total IgG, IgM, and IgG subclass responses were measured just before the malaria transmission season. The incidence of malaria was 2.4 episodes per child year of risk. After adjusting for the confounding effects of age, the level of total IgG to GLURP was strongly associated with reduced malaria incidence (incidence rate ratio associated with a doubling of total IgG, 0.79; 95% confidence interval, 0.66 to 0.94; P = 0.009.); there was a borderline statistically significant association between the level of total IgG to MSP3 and malaria incidence and no evidence of an association for total IgG to AMA1 and to MSP1-19. Of the IgG subclass responses studied, only IgG3 and IgG4 against GLURP and IgG1 against AMA1 were associated with reduced risk of clinical malaria. There was no evidence of an interaction between responses to AMA1 and baseline parasitemia in their effects on malaria incidence. Currently included in malaria vaccine formulations for clinical trials in humans, these blood-stage antigens, AMA1 and GLURP, offer good prospects for malaria vaccine development.
                Bookmark

                Author and article information

                Contributors
                adamou.rafiou@gmail.com
                Journal
                Malar J
                Malar. J
                Malaria Journal
                BioMed Central (London )
                1475-2875
                11 June 2019
                11 June 2019
                2019
                : 18
                : 194
                Affiliations
                [1 ]ISNI 0000 0001 2171 2558, GRID grid.5842.b, MERIT, IRD, , Université de Paris, ; 75006 Paris, France
                [2 ]ISNI 0000 0001 0382 0205, GRID grid.412037.3, Centre d’Etude et de Recherche sur le Paludisme Associé à la Grossesse et à l’Enfance, Faculté des Sciences de la Santé, , Université d’Abomey-Calavi, ; Cotonou, Benin
                [3 ]ISNI 0000 0001 0382 0205, GRID grid.412037.3, Laboratoire de Biochimie et de Biologie Moléculaire, Faculté des Sciences et Techniques, , Université d’Abomey-Calavi, ; Abomey Calavi, Benin
                [4 ]ISNI 0000 0001 0382 0205, GRID grid.412037.3, Laboratoire de Biologie et Physiologie Cellulaires, Faculté des Sciences et Techniques, , Université d’Abomey-Calavi, ; Cotonou, Benin
                [5 ]ISNI 0000 0004 1937 0722, GRID grid.11899.38, Division of Clinical Immunology, School of Medicine of Ribeirão Preto, , University of São Paulo, ; São Paulo, Brazil
                [6 ]ISNI 0000 0004 0417 4147, GRID grid.6203.7, Department for Congenital Disorders, , Statens Serum Institut, ; Copenhagen, Denmark
                [7 ]ISNI 0000 0001 0674 042X, GRID grid.5254.6, Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology, , University of Copenhagen, ; Copenhagen, Denmark
                [8 ]GRID grid.475435.4, Department of Infectious Diseases, , Copenhagen University Hospital, Rigshospitalet, ; Copenhagen, Denmark
                [9 ]ISNI 0000 0004 0625 2495, GRID grid.11184.3d, Department of Parasitology, , Biomedical Primate Research Centre, ; Rijswijk, The Netherlands
                [10 ]ISNI 0000 0001 2353 6535, GRID grid.428999.7, Laboratoire de Vaccinologie-Parasitaire, , Institut Pasteur, ; Paris, France
                [11 ]ISNI 0000 0001 2308 1657, GRID grid.462844.8, Laboratoire de Probabilités et Modèles aléatoires (LPMA), UMR CNRS 7599, , UPMC, ; Paris, France
                Author information
                http://orcid.org/0000-0001-5506-1095
                Article
                2831
                10.1186/s12936-019-2831-x
                6560827
                31185998
                11fb848d-bfeb-4a3b-962c-0868d6dab59b
                © The Author(s) 2019

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 11 March 2019
                : 4 June 2019
                Funding
                Funded by: Ambassade de France au Bénin
                Categories
                Research
                Custom metadata
                © The Author(s) 2019

                Infectious disease & Microbiology
                plasmodium falciparum,malaria,cytophilic igg,merozoite vaccine candidate antigens

                Comments

                Comment on this article